AstraZeneca | Financial Times

0

AstraZeneca’s vaccine has saved many thousands of lives. But rare side-effects, and, relative to competitors, lower efficacy against new variants have given it an uncertain outlook. Coupled with a multibillion-euro lawsuit over delivery shortfalls, the UK pharma group’s future role in the ongoing battle against Covid-19 is under scrutiny

FOLLOW US ON GOOGLE NEWS

 

Source

Comments
Loading...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. AcceptRead More

Privacy & Cookies Policy